Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan, plc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market 28 additional styles of Natrelle® 410 silicone-filled breast implants, giving surgeons and patients more options to achieve desired outcomes. The FDA approved extra-full projection styles (X), along with additional low projection, low height styles (L) from the Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implant line, for use in breast reconstruction, augmentation and revision surgery.

Designed to mirror the shape of a woman's breast, the Natrelle® 410 Shaped Gel Breast Implants are filled with a highly cohesive silicone gel which enables the implants to have long-lasting shape over time. The additional projection styles offer surgeons more options to better meet the individual needs of each patient.

"The FDA approval of additional Natrelle® 410 shaped gel implants is further proof of Allergan's long-standing and continued commitment to medical aesthetics and plastic surgery," said David Nicholson, Executive Vice President. "Natrelle® 410 breast implants are the most selected shaped gel implants in the United States."

The approval of the X and L projection styles adds to a wide range of breast reconstruction, augmentation and revision surgical options across the Natrelle® 410 Shaped Gel Breast Implants line. The complete 12 style matrix includes three heights and four projection styles, including a 7.1 cm option – the highest projecting implant available in the U.S., giving surgeons and patients more options to achieve desired outcomes.

The FDA approval of additional Natrelle® 410 shaped gel implant styles is based on 3-year data from a study of over 350 women who underwent breast reconstruction, augmentation or revision surgery with the previously approved range of Natrelle® 410 breast implants.

These additional implant styles will be available to surgeons and patients in October 2015. Allergan requires surgeons to complete a certification program, which includes instruction on surgical techniques and patient selection, before they are able to offer Natrelle® 410 breast implants to their patients.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits